Early Prediction of Oral Cancer by S100A7 Immunohistochemistry Signature-based Assessment
ConditionOral Neoplasm
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age15-90
SponsorProteocyte Diagnostics Inc.
About this trial
The purpose of this observational study is to evaluate the utility of the S100A7 immunohistochemistry signature-based assessment - STRATICYTE - in determining the risk of progression to cancer of clinically suspicious oral lesions.
Eligibility criteria
Qualifiers
Any clinically suspicious lesion biopsied to rule-out oral epithelial dysplasia/oral squamous cell carcinoma
Disqualifiers
Biopsied lesion with or without dysplasia concomitant with oral squamous cell carcinoma at initial biopsy
Trial design
Treatments tested in this trial
- Standard of Care Histopathology
- STRATICYTE Assessment
Treatment groups
500 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov